Effects of Treatments on Atopic Dermatitis
Effects of Treatments on the Microbiome in Healthy Volunteers and Patients With Atopic Dermatitis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
130 participants
Sep 18, 2012
INTERVENTIONAL
Conditions
Summary
Background: \- Atopic dermatitis, or eczema, is a chronic skin disorder. Patients sometimes have infections with S. aureus bacteria. Researchers want to study how eczema treatments affect the number and the type of bacteria on the skin. Objectives: \- To study the effect of eczema treatments on skin bacteria. Eligibility: * Individuals between 2 and 25 years of age who have moderate to severe atopic dermatitis. * Healthy volunteers between 18 and 40 years of age with no history of eczema. Design: * Participants will be screened with a physical exam and medical history. Research samples will be collected. Skin biopsies may also be performed. * All participants will be assigned to one of several study groups. * Healthy volunteers must not have taken antibiotics in the year before the start of the study. * All participants will have regular study visits during their 1-year participation. More research samples will be collected at these visits. * Healthy volunteers may be asked to come in for a one-time follow up after the 1 year mark.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
800/160 orally every 12 hours for 14 days
500 mg orally every 8 hours for 14 days
20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
6 % dilute bleach
Capsule orally every 8 hours daily for 14 days
Three times a week for 14 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT01631617